A growing number of Americans who began taking popular weight-loss drugs like Ozempic and Wegovy are stopping, and experiencing rapid weight regain, according to recent data and reports from health professionals.
KFF Health News reported that older Americans, in particular, are discontinuing utilize of glucagon-like peptide-1 (GLP-1) receptor agonists at significant rates. The drugs, initially developed for managing type 2 diabetes, gained widespread attention for their effectiveness in promoting weight loss. However, the convenience and cost associated with maintaining the prescriptions appear to be significant factors in discontinuation.
A study published in Scientific American found that both weight loss and associated health benefits, such as improved blood sugar control and reduced blood pressure, diminish quickly after stopping the medications. Researchers observed that individuals regained a substantial portion of lost weight within months of ceasing treatment. The study underscores the ongoing nature of the condition and the need for continued medical intervention or lifestyle changes to sustain results.
The shift in medication use is also impacting consumer behavior, according to researchers at Cornell University. They have observed changes in the types of foods Americans are purchasing, with a decrease in demand for highly palatable, processed foods and an increase in purchases of fruits and vegetables among those actively taking GLP-1 drugs. This suggests the medications may be altering food preferences, though the long-term effects of these changes remain unclear.
The American Psychological Association has begun to examine the mental health implications of these drugs, noting a “new era of weight loss” that requires attention to psychological well-being. The association’s research indicates that while the drugs can be effective, they also present unique challenges related to body image, eating behaviors, and potential psychological dependence.
As of February 25, 2026, no official statement has been released by the Food and Drug Administration regarding the observed increase in discontinuation rates or potential strategies to address the challenges associated with long-term GLP-1 receptor agonist use. Further research is planned to assess the long-term health outcomes of individuals who discontinue these medications.
